跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT02944383
NCT02944383已完成2 期

A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)

NeuroBo Pharmaceuticals Inc.46 个研究点 分布在 2 个国家目标入组 91 人开始时间: 2016年12月最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
91
试验地点
46
主要终点
Percent Change From Baseline to End of Study (EOS) in Fasting Serum Triglycerides (TG)
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects with Severe Hypertriglyceridemia (INDIGO-1)

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 —（Adult, Older Adult）
性别
All
接受健康志愿者
否

入选标准

  • •Subjects who meet all of the following criteria will be eligible to participate in the study:
  • •Provision of written and signed informed consent (by subject or legal guardian) prior to any study-specific procedure;
  • •Male or female (neither pregnant or lactating) ≥18 years of age at time of consent;
  • •Women of child-bearing potential must have a negative serum pregnancy test at the Screening Visit and negative urine dipstick on Study Day 1 prior to dosing in order to qualify for the study. Women who are surgically sterile or are clinically confirmed to be post-menopausal (i.e., documented amenorrhea for ≥ 1 year in the absence of other biological or physiological causes) are not considered to be of child-bearing potential;
  • •Women of child-bearing potential must agree to use acceptable methods of contraception throughout the duration of the study and for 30 days after the last dose of study drug. For this study, double-barrier contraception is required.
  • •Currently on a self-reported, stable, low-fat, low-cholesterol diet in combination with stable statins with or without ezetimibe (10 mg QD) for at least 12 weeks prior to the Screening Visit;
  • •Mean fasting TG value ≥ 500 mg/dL to < 1500 mg/dL (with the higher value no more than 50% greater than the lower value) from the S1 and S2 Visits (or alternatively S2 and S3);
  • •Physical examination, including vital signs, that is within normal limits or clinically acceptable to the Investigator;
  • •Weight ≥ 50 kg; with a body mass index (BMI) ≤ 45 kg/m²; and
  • •Subjects with Type 2 diabetes who take anti-diabetes pharmacologic therapy must be on a stable a regimen for at least 3 months, with no planned changes in medications for the study duration.

排除标准

  • •Subjects who meet any of the following criteria will be excluded from participation in the study:
  • •Known and previously documented homozygous genetic deficiencies (LPL, ApoC-II, ApoC-III, ApoA-V, GPIHBP1, or LMF1);
  • •History of pancreatitis within the last 6 months prior to screening (Visit S1);
  • •History of bariatric surgery; symptomatic gallstone disease, unless treated with cholecystectomy;
  • •Abnormal liver function test at the Pre-Screening Visit or any of the Screening Visits (aspartate aminotransferase or alanine aminotransferase > 2 × the upper limit of normal [ULN], total bilirubin > 1.5 × ULN, or alkaline phosphatase > 2 × ULN based on appropriate age and gender normal values). Subjects with bilirubin > 1.5 × ULN and history of Gilbert's syndrome may be included; reflexive direct bilirubin testing will be used to confirm Gilbert's syndrome;
  • •Active liver disease (e.g., cirrhosis, alcoholic liver disease, hepatitis B [HBV], hepatitis C [HCV], autoimmune hepatitis, liver failure, liver cancer), history of liver transplant, known diagnosis of human immunodeficiency virus (HIV), or acquired immune deficiency virus;
  • •Moderate to severe renal insufficiency defined as an estimated GFR < 60 mL/min/1.73 m2 (calculated using The Chronic Kidney Disease Epidemiology Collaboration equation) at the Pre-Screening Visit or at any of the Screening Visits;
  • •Abnormal urinalysis (proteinuria greater than trace or any male or non-menstruating female with greater than trace hematuria), confirmed by reflexive urine protein:creatinine ratio testing;
  • •Uncontrolled thyroid disease: hyperthyroidism or hypothyroidism as defined by thyroid stimulating hormone (TSH) below the lower limit of normal or > 1.5 × ULN, respectively, based on results from the Pre-Screening Visit or the Screening Visit. If controlled, treatment should be stable for at least 3 months prior to the Screening Visit;
  • •Type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitus HbA1c value ≥8.5% based on results from the Pre-Screening Visit or the Screening Visit), or any diabetic subject taking a thiazolidinedione (e.g., pioglitazone, rosiglitazone);
  • •New York Heart Association Class III or IV heart failure (see Appendix C);
  • •Myocardial infarction, severe or unstable angina pectoris, coronary angioplasty, coronary artery bypass graft, or other major cardiovascular events resulting in hospitalization within 3 months of the Screening Visit (S1). Subjects with adequately treated stable angina, per Investigator assessment, may be included;
  • •Uncontrolled cardiac arrhythmia or prolonged QT on the Screening Visit or Study Day 1 prior to dosing ECG (QTcF > 450 msec for men and >470 msec for women) or known family history of prolonged QT or unexplained sudden cardiac death;
  • •Uncontrolled hypertension, defined as sitting systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg, and confirmed by repeat measurement;
  • •Currently receiving cancer treatment(s) or, in the Investigator's opinion, at risk of relapse for recent cancer;
  • •Inadequate washout of a PCSK9 inhibitor (8 weeks prior to the Screening Visit S1), a fibrate lipid lowering agent (6 weeks prior to the Screening Visit S1), niacin > 200 mg/day, OMG-3, bile acid sequestrants or other lipid lowering therapies (4 weeks prior to the Screening Visit S1);
  • •Use of any excluded medications or supplements within 3 months prior to S1 (e.g., potent cytochrome P450 [CYP] 3A4 inhibitors, see Appendix D);
  • •Hypersensitivity to or a history of significant adverse reactions to any fibrate lipid regulating agent;
  • •History of drug or alcohol abuse within the past year or inability to comply with protocol requirements, including subject alcohol restrictions (see Section 5.6.3);
  • •Previously treated with gemcabene (i.e., CI-1027); participation in another clinical study of an investigational agent or device concurrently or within 1 month prior to the Screening Visit, or use of an investigational agent within 1 month or 5 half-lives (if known), whichever is longer, prior to the Screening Visit; or
  • •Any other finding which, in the opinion of the Investigator, would compromise the subject's safety or participation in the study.

研究组 & 干预措施

Gemcabene 300 mg

Experimental

Participants received 300 mg Gemcabene orally, once daily for 12 weeks.

干预措施: Gemcabene (Drug)

Gemcabene 600 mg

Experimental

Participants received 600 mg Gemcabene orally, once daily for 12 weeks.

干预措施: Gemcabene (Drug)

Placebo

Placebo Comparator

Participants received matching placebo orally, once daily for 12 weeks.

干预措施: Placebo (Drug)

结局指标

主要结局

Percent Change From Baseline to End of Study (EOS) in Fasting Serum Triglycerides (TG)

时间窗: Baseline, EOS (average of week 10 and 12)

EOS was defined as the average of the week 10 and week 12 values. If either the week 10 or week 12 value was missing, then the single value (week 10 or week 12) was used. Completely missing values (both week 10 and week 12) were imputed using last observation carried forward (LOCF).

次要结局

  • Percent Change From Baseline in Fasting Serum TG(Baseline, Weeks 2, 6, 10 and 12)
  • Percent Change From Baseline in VLDL-C(Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12))
  • Change From Baseline in VLDL-C(Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12))
  • Percent Change From Baseline in HDL-C(Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12))
  • Change From Baseline in Fasting Serum TG(Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12))
  • Percent Change From Baseline in TC(Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12))
  • Change From Baseline in TC(Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12))
  • Change From Baseline in Non-HDL-C(Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12))
  • Change From Baseline in Apolipoprotein B(Baseline, Weeks 10, 12 and EOS (average of week 10 and 12))
  • Percent Change From Baseline in Apolipoprotein A-I(Baseline, Weeks 10, 12 and EOS (average of week 10 and 12))
  • Percent Change From Baseline in Apolipoprotein A-II(Baseline, Weeks 10, 12 and EOS (average of week 10 and 12))
  • Change From Baseline in Apolipoprotein A-II(Baseline, Weeks 10, 12 and EOS (average of week 10 and 12))
  • Percent Change From Baseline in Non-HDL-C(Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12))
  • Change From Baseline in Apolipoprotein A-I(Baseline, Weeks 10, 12 and EOS (average of week 10 and 12))
  • Percent Change From Baseline in Apolipoprotein C-II(Baseline, Weeks 10, 12 and EOS (average of week 10 and 12))
  • Change From Baseline in Apolipoprotein C-II(Baseline, Weeks 10, 12 and EOS (average of week 10 and 12))
  • Percent Change From Baseline in Apolipoprotein E(Baseline, Weeks 10, 12 and EOS (average of week 10 and 12))
  • Change From Baseline in LDL-C(Baseline, Weeks 10, 12 and EOS (average of week 10 and 12))
  • Percent Change From Baseline in Lipoprotein Particle Number(Baseline, Week 12)
  • Percent Change From Baseline in HDL Particle Number(Baseline, Week 12)
  • Change From Baseline in HDL-C(Baseline, Weeks 2, 6, 10, 12 and EOS (average of week 10 and 12))
  • Change From Baseline in LDL-TG(Baseline, Weeks 10, 12 and EOS (average of week 10 and 12))
  • Percent Change From Baseline in HDL-TG(Baseline, Weeks 10, 12 and EOS (average of week 10 and 12))
  • Percent Change From Baseline in High-sensitivity C-reactive Protein(Baseline, Weeks 10, 12 and EOS (average of week 10 and 12))
  • Percent Change From Baseline in Apolipoprotein B(Baseline, Weeks 10, 12 and EOS (average of week 10 and 12))
  • Percent Change From Baseline in LDL-TG(Baseline, Weeks 10, 12 and EOS (average of week 10 and 12))
  • Change From Baseline in VLDL-TG(Baseline, Weeks 10, 12 and EOS (average of week 10 and 12))
  • Change From Baseline in HDL Particle Number(Baseline, Week 12)
  • Percent Change From Baseline in Fibrinogen(Baseline, Weeks 10, 12 and EOS (average of week 10 and 12))
  • Percent Change From Baseline in Interleukin-6(Baseline, Weeks 10, 12 and EOS (average of week 10 and 12))
  • Change From Baseline in Interleukin-6(Baseline, Weeks 10, 12 and EOS (average of week 10 and 12))
  • Percent Change From Baseline in Apolipoprotein C-III(Baseline, Weeks 10, 12 and EOS (average of week 10 and 12))
  • Percent Change From Baseline in Lipoprotein Size(Baseline, Week 12)
  • Change From Baseline in Lipoprotein Size(Baseline, Week 12)
  • Change From Baseline in Lipoprotein Particle Number(Baseline, Week 12)
  • Change From Baseline in High-sensitivity C-reactive Protein(Baseline, Weeks 10, 12 and EOS (average of week 10 and 12))
  • Change From Baseline in Serum Amyloid A(Baseline, Weeks 10, 12 and EOS (average of week 10 and 12))
  • Percent Change From Baseline in Adiponectin(Baseline, Week 12 and EOS (average of week 10 and 12))
  • Percent Change From Baseline in Angiopoietin 4(Baseline, Week 12 and EOS (average of week 10 and 12))
  • Change From Baseline in Apolipoprotein C-III(Baseline, Weeks 10, 12 and EOS (average of week 10 and 12))
  • Change From Baseline in Apolipoprotein E(Baseline, Weeks 10, 12 and EOS (average of week 10 and 12))
  • Percent Change From Baseline in LDL-C(Baseline, Weeks 10, 12 and EOS (average of week 10 and 12))
  • Percent Change From Baseline in VLDL-TG(Baseline, Weeks 10, 12 and EOS (average of week 10 and 12))
  • Change From Baseline in HDL-TG(Baseline, Weeks 10, 12 and EOS (average of week 10 and 12))
  • Change From Baseline in Fibrinogen(Baseline, Weeks 10, 12 and EOS (average of week 10 and 12))
  • Percent Change From Baseline in Serum Amyloid A(Baseline, Weeks 10, 12 and EOS (average of week 10 and 12))
  • Change From Baseline in Adiponectin(Baseline, Week 12 and EOS (average of week 10 and 12))
  • Percentage of Participants Achieving a TG Value < 500 mg/dL (5.65 mmol/L)(Weeks 10, 12 and EOS (average of week 10 and 12))
  • Change From Baseline in Angiopoietin 4(Baseline, Week 12 and EOS (average of week 10 and 12))

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (46)

Loading locations...

相似试验

已完成
2 期
Treatment of Moderate to Severe Facial Acne VulgarisAcne Vulgaris
NCT00612573Warner Chilcott257
招募中
2 期
Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory MyopathyPolymyositisIdiopathic Inflammatory MyopathiesDermatomyositis
NCT05833711Immunoforge Co. Ltd.39
已完成
2 期
Phase 2b Study of GAM501 in the Treatment of Diabetic Ulcers of the Lower ExtremitiesDiabetic Foot
NCT00493051Tissue Repair Company124
终止
2 期
Study in Adult Asthmatic Patients With Allergic Bronchopulmonary AspergillosisAllergic Bronchopulmonary Aspergillosis
NCT03960606Pulmatrix Inc.7
终止
2 期
A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS)Hidradenitis Suppurativa
NCT05348681Aristea Therapeutics, Inc.25